相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。The ATM and ATR kinases regulate centrosome clustering and tumor recurrence by targeting KIFC1 phosphorylation
Guangjian Fan et al.
NATURE COMMUNICATIONS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
100MO Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer: The phase II randomized PIPSeN trial
S. Postel-Vinay et al.
Journal of Thoracic Oncology (2021)
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
Mihaela Aldea et al.
CANCER DISCOVERY (2021)
Repositioning PARP inhibitors in the treatment of thoracic malignancies
Francesco Passiglia et al.
CANCER TREATMENT REVIEWS (2021)
Preoperative clinical and tumor genomic features associated with pathologic lymph node metastasis in clinical stage I and II lung adenocarcinoma
Raul Caso et al.
NPJ PRECISION ONCOLOGY (2021)
Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model
Vincent Faugeroux et al.
NATURE COMMUNICATIONS (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Exploitation of the chick embryo chorioallantoic membrane (CAM) as a platform for anti-metastatic drug testing
P. Pawlikowska et al.
SCIENTIFIC REPORTS (2020)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer
C. R. Lindsay et al.
EUROPEAN JOURNAL OF CANCER (2019)
CTC-Derived Models: A Window into the Seeding Capacity of Circulating Tumor Cells (CTCs)
Tala Tayoun et al.
CELLS (2019)
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
Nicolas Marcoux et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
State-of-the-art strategies for targeting the DNA damage response in cancer
Patrick G. Pilie et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Loss of E-cadherin provides tolerance to centrosome amplification in epithelial cancer cells
Alexander D. Rhys et al.
JOURNAL OF CELL BIOLOGY (2018)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
Benjamin J. Drapkin et al.
CANCER DISCOVERY (2018)
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Theo A. Knijnenburg et al.
CELL REPORTS (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Benjamin H. Lok et al.
CLINICAL CANCER RESEARCH (2017)
Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
June-Koo Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Integrative clinical genomics of metastatic cancer
Dan R. Robinson et al.
NATURE (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer
M. Jamal-Hanjani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Emmet J. Jordan et al.
CANCER DISCOVERY (2017)
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
C. Allison Stewart et al.
ONCOTARGET (2017)
Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study
C. J. Morrow et al.
ANNALS OF ONCOLOGY (2016)
Metastatic colonization by circulating tumour cells
Joan Massague et al.
NATURE (2016)
Repair Pathway Choices and Consequences at the Double-Strand Break
Raphael Ceccaldi et al.
TRENDS IN CELL BIOLOGY (2016)
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Junko Murai et al.
ONCOTARGET (2016)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
Cassandra L. Hodgkinson et al.
NATURE MEDICINE (2014)
OPINION Challenges in circulating tumour cell research
Catherine Alix-Panabieres et al.
NATURE REVIEWS CANCER (2014)
Discovery and Mechanistic Study of a Small Molecule Inhibitor for Motor Protein KIFC1
Jiaquan Wu et al.
ACS CHEMICAL BIOLOGY (2013)
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay
Irene Baccelli et al.
NATURE BIOTECHNOLOGY (2013)
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Marcin Imielinski et al.
CELL (2012)
The potential of exploiting DNA-repair defects for optimizing lung cancer treatment
Sophie Postel-Vinay et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non-Small-Cell Lung Cancer
Matthew G. Krebs et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A mechanism linking extra centrosomes to chromosomal instability
Neil J. Ganem et al.
NATURE (2009)
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing
Andreas Gnirke et al.
NATURE BIOTECHNOLOGY (2009)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2008)
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding et al.
NATURE (2008)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)